BOEHRINGER MANNHEIM/LILLY DIABETES CO-PROMOTION ALLIANCE
This article was originally published in The Gray Sheet
Executive Summary
BOEHRINGER MANNHEIM/LILLY DIABETES CO-PROMOTION ALLIANCE will focus on co-promotion of B-M's Accu-Chek blood glucose monitoring devices and Lilly's Humulin insulin products in the U.S. Sales forces are being trained in both product lines with the goal of integrating insulin and glucose monitoring therapies, B-M reported. Lilly said sales reps are already co-promoting the products in the field.
You may also be interested in...
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.